Immediate Impact
65 standout
Citing Papers
The promising role of tumor-associated macrophages in the treatment of cancer
2024 Standout
The present and future of bispecific antibodies for cancer therapy
2024 Standout
Works of X. Li being referenced
1300P A phase Ib/II trial of AK104 (PD-1/CTLA-4 bispecific antibody) in combination with anlotinib in advanced NSCLC
2021
1278P SHR-1701, a bifunctional fusion protein targeting PD-L1 and TGF-β, as first-line therapy for PD-L1+ advanced/metastatic NSCLC: Data from a clinical expansion cohort of a phase I study
2021
Author Peers
| Author | Last Decade | Papers | Cites | |||
|---|---|---|---|---|---|---|
| X. Li | 145 | 105 | 42 | 33 | 189 | |
| Haiyi Deng | 158 | 143 | 26 | 31 | 216 | |
| Takehiro Tozuka | 191 | 145 | 28 | 33 | 233 | |
| David Vicente Baz | 160 | 129 | 46 | 26 | 219 | |
| Loïck Galland | 178 | 77 | 58 | 24 | 280 | |
| Masayuki Shirasawa | 157 | 100 | 26 | 25 | 200 | |
| Yuki Takeyasu | 163 | 130 | 27 | 28 | 229 | |
| Ryota Shibaki | 232 | 181 | 31 | 23 | 299 | |
| M. Dómine Gómez | 197 | 120 | 71 | 35 | 257 | |
| Ina Valeria Zurlo | 99 | 85 | 35 | 23 | 181 | |
| Hélène Vanacker | 83 | 92 | 52 | 32 | 214 |
All Works
Login with ORCID to disown or claim papers
Loading papers...